Return on Equity (ROE)
since 2013
Paying user area
Try for free
IQVIA Holdings Inc. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Balance Sheet: Assets
- Common Stock Valuation Ratios
- Dividend Discount Model (DDM)
- Operating Profit Margin since 2013
- Current Ratio since 2013
- Total Asset Turnover since 2013
- Price to Operating Profit (P/OP) since 2013
- Price to Book Value (P/BV) since 2013
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to IQVIA Holdings Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
IQVIA Holdings Inc., ROE, long-term trends, calculation
| ROE | = | 100 | × | Net income attributable to IQVIA Holdings Inc.1 | ÷ | Equity (deficit) attributable to IQVIA Holdings Inc.’s stockholders1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2022 | = | 100 | × | ÷ | |||
| Dec 31, 2021 | = | 100 | × | ÷ | |||
| Dec 31, 2020 | = | 100 | × | ÷ | |||
| Dec 31, 2019 | = | 100 | × | ÷ | |||
| Dec 31, 2018 | = | 100 | × | ÷ | |||
| Dec 31, 2017 | = | 100 | × | ÷ | |||
| Dec 31, 2016 | = | 100 | × | ÷ | |||
| Dec 31, 2015 | = | 100 | × | ÷ | |||
| Dec 31, 2014 | = | 100 | × | ÷ | |||
| Dec 31, 2013 | = | 100 | × | ÷ |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
1 US$ in millions
- Net Income
-
The net income attributable to the company experienced notable fluctuations over the period from 2013 to 2022. Initially, net income showed moderate values ranging from 227 million USD in 2013 to 387 million USD in 2015. A significant drop occurred in 2016, with net income decreasing sharply to 115 million USD. From 2017 onwards, there was considerable volatility, with a peak at 1,309 million USD in 2017 followed by a decline to 259 million USD in 2018. Subsequent years displayed variability with net income rising moderately to 279 million USD in 2020, then increasing substantially again to 966 million USD in 2021 and reaching 1,091 million USD in 2022. This trend indicates periods of both high profitability and challenging financial performance within the decade.
- Equity (Deficit) Attributable to Stockholders
-
The equity attributable to the company’s stockholders showed a marked shift starting in 2016. From a negative position in prior years (-667 million USD in 2013, -704 million USD in 2014, and -564 million USD in 2015), equity improved dramatically to a positive 8,633 million USD in 2016. However, following this peak, equity gradually declined year-over-year to 5,765 million USD by 2022. This decline suggests possible distributive transactions, impairments, or other equity-reducing events after the peak in 2016, although the company maintained a positive equity balance throughout the latter part of the period.
- Return on Equity (ROE)
-
Return on Equity data is available from 2016 onwards and shows substantial variation. The ROE was 1.33% in 2016 before rising sharply to 16.14% in 2017. The metric then decreased in 2018 and 2019 to 3.86% and 3.18%, respectively. From 2020, ROE demonstrated a recovery trend, increasing to 4.65%, then significantly rising to 15.99% in 2021 and ultimately reaching 18.92% in 2022. The overall improvement in ROE during the later years suggests enhanced profitability relative to stockholders’ equity and an efficient use of equity capital following the initial period of low returns.
- Summary of Financial Trends
-
Overall, the financial data reflect a company experiencing phases of significant transformation. The shift from negative equity to positive equity in 2016 represents a fundamental change in financial structure. Net income shows a pattern of volatility but with marked improvement in recent years, particularly in 2021 and 2022, which corresponds with rising ROE values. Despite some declines in equity after its 2016 peak, profitability indicators suggest growing efficiency and a stronger return on investment for shareholders toward the end of the examined period.
Comparison to Competitors
IQVIA Holdings Inc., ROE, long-term trends, comparison to competitors
| IQVIA Holdings Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2022 | |||||||||||||
| Dec 31, 2021 | |||||||||||||
| Dec 31, 2020 | |||||||||||||
| Dec 31, 2019 | |||||||||||||
| Dec 31, 2018 | |||||||||||||
| Dec 31, 2017 | |||||||||||||
| Dec 31, 2016 | |||||||||||||
| Dec 31, 2015 | |||||||||||||
| Dec 31, 2014 | |||||||||||||
| Dec 31, 2013 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
IQVIA Holdings Inc., ROE, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| IQVIA Holdings Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2022 | ||
| Dec 31, 2021 | ||
| Dec 31, 2020 | ||
| Dec 31, 2019 | ||
| Dec 31, 2018 | ||
| Dec 31, 2017 | ||
| Dec 31, 2016 | ||
| Dec 31, 2015 | ||
| Dec 31, 2014 | ||
| Dec 31, 2013 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Industry (Health Care)
IQVIA Holdings Inc., ROE, long-term trends, comparison to industry (health care)
| IQVIA Holdings Inc. | Health Care | |
|---|---|---|
| Dec 31, 2022 | ||
| Dec 31, 2021 | ||
| Dec 31, 2020 | ||
| Dec 31, 2019 | ||
| Dec 31, 2018 | ||
| Dec 31, 2017 | ||
| Dec 31, 2016 | ||
| Dec 31, 2015 | ||
| Dec 31, 2014 | ||
| Dec 31, 2013 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).